z-logo
Premium
The human granulocyte/macrophage colony‐stimulating factor receptor α2 isoform influences haemopoietic lineage commitment and divergence
Author(s) -
Slater Nicholas J.,
Yamaguchi Masafumi,
Rothwell Dominic G.,
Baker Patrick,
Heyworth Clare M.,
Chopra Rajesh
Publication year - 2003
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2003.04383.x
Subject(s) - granulocyte colony stimulating factor receptor , haematopoiesis , biology , granulocyte macrophage colony stimulating factor receptor , progenitor cell , cd34 , gene isoform , granulocyte macrophage colony stimulating factor , cellular differentiation , receptor , granulocyte , microbiology and biotechnology , interleukin 3 , colony stimulating factor , immunology , stem cell , macrophage , macrophage colony stimulating factor , cytokine , in vitro , t cell , antigen presenting cell , immune system , gene , genetics
Summary. A number of alternatively spliced isoforms of haemopoietic growth factor receptors (HGFRs) have been described, but their role in human haemopoiesis remains undetermined. We have investigated the relative expression of the α1 and α2 isoforms of human granulocyte/macrophage colony‐stimulating factor receptor (hGM‐CSFR) during haemopoietic cell differentiation, and have shown that both subunits are independently regulated during differentiation of CD34 + human haemopoietic progenitor cells. To further investigate these ex‐vivo observations, we established a series of murine FDCP mix cell lines, which, as a consequence of the ectopic expression of α1 or α2 hGM‐CSFR, demonstrated differential differentiation responses to hGM‐CSF. In this model system, hGM‐CSFR‐α2‐expressing cells showed increased hGM‐CSF‐mediated erythroid/megakaryocytic differentiation compared with hGM‐CSFR‐α1‐expressing cells.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here